Evidence map›Paper›PMID 28556546›Full record

ArticleCancer medicine2017

A state-wide initiative to promote genetic testing in an underserved population.

Meghan L Underhill, Traci M Blonquist, Karleen Habin, Debra Lundquist, Kristen Shannon, Kathryn Robinson, Mary-Lou Woodford, Jean Boucher

Open access · goldAbstract read
In one paragraph

Article in Cancer medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.9field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 10 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 1 country.

Meghan L UnderhillDana-Farber Cancer Institute, 450 Brookline Ave LW522, Boston, Massachusetts, 02115.ORCID http://orcid.org/0000-0002-1433-5915
Traci M BlonquistDana-Farber Cancer Institute, 450 Brookline Ave LW522, Boston, Massachusetts, 02115.
Karleen HabinMassachusetts General Hospital, Boston, MA, USA.
Debra LundquistBoston College, Connell School of Nursing, Cancer Resource Foundation, Chestnut Hill, MA, USA.
Kristen ShannonMassachusetts General Hospital, Boston, MA, USA.
Kathryn RobinsonSchool of Nursing, Northeastern University, Boston, MA, USA.
Mary-Lou WoodfordCancer Resource Foundation, Marlborough, MA, USA.
Jean BoucherDana-Farber Cancer Institute, 450 Brookline Ave LW522, Boston, Massachusetts, 02115.
Dana-Farber Cancer Institute · USMassachusetts General Hospital · USBoston College · USNortheastern University · USResource Foundation · USUniversity of Massachusetts Chan Medical School · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Genetic testing for cancer susceptibility has been widely studied and utilized clinically. Access to genetic services in research and practice is largely limited to well-insured, Caucasian individuals. In 2009, the Cancer Resource Foundation (CRF) implemented the Genetic Information for Treatment Surveillance and Support (GIFTSS) program to cover the out-of-pocket expenses associated with cancer genetic testing, targeting high-risk individuals with limited financial means and limited health insurance coverage. Here, we (i) describe the characteristics of participants in the Massachusetts (MA) GIFTSS program and (ii) evaluate mutations found in this diverse sample. A secondary retrospective data analysis was performed using de-identified demographic data obtained from laboratory requisition forms and cancer genetic testing result information from the laboratory source. Eligible participants were those who utilized the MA GIFFTS program from 2009 through December of 2014. Data were summarized using descriptive measures of central tendency. Participants were residents of Massachusetts who had health insurance and had a reported income within 250-400% of the federal poverty level. Genetic testing results were categorized following clinical guidelines. Overall, 123 (13%) of participants tested positive for a mutation in a cancer susceptibility gene. For those with a cancer diagnosis, 65 (12%) were found to have a positive result and 20 (7%) had a variant of uncertain significance (VUS). For those unaffected patients, 58 (15%) had a positive result and 10 (3%) were found to have a VUS. The results from this study are useful in describing genetic testing outcomes in this high-risk underserved community. Repeatedly, the literature reports that individuals from diverse or limited resource settings are less likely to access genetic testing. Continued research efforts should be devoted to promoting the access of genetic testing in the high-risk, underserved community.

Indexed as

Genetic TestingHealth PromotionVulnerable PopulationsAdolescentAdultAgedAged, 80 and overChildChild, PreschoolFemaleGenetic Predisposition to DiseaseHealthcare DisparitiesHumansMaleMassachusettsMiddle AgedCancerdisease susceptibilitygenetic testinghealthcare disparitynursing research

Identifiers

PMID28556546
PMCPMC5504327
OpenAlexW2619615880

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.